PharmaCyte Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMCB research report →
Price Chart
About the company
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites.
- CEO
- Joshua N. Silverman
- IPO
- 2013
- Employees
- 2
- HQ
- Las Vegas, NV, US
Get TickerSpark's AI analysis on PMCB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.52M
- P/E
- -0.17
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.15
- EV/EBITDA
- 2.47
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -50.84%
- ROIC
- -14.92%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-6,853,713
- Net Income
- $-19,424,654-163.4%
- EPS
- $-2.77-186.8%
- OCF Growth
- -73.0%
- FCF Growth
- -73.0%
- 52W High
- $1.51
- 52W Low
- $0.50
- 50D MA
- $0.66
- 200D MA
- $0.75
- Beta
- 0.68
- RSI (14)
- 28
- Avg Volume
- 129.61K
No earnings-call transcripts are available for PMCB yet.
- Free Float
- 92.8%
- Shares Outstanding
- 10.74M
- Float Shares
- 9.96M
of shares held by institutions
27 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 74.92K | 0 |
| Accredited Wealth Management, LLC | 50 | ▲ 50 |
| Cwm, LLC | 1 | ▲ 1 |
Held by 4 ETFs
Biggest fund positions in PMCB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | WALKER WAYNE REMELL | other | 0 |
| Mar 31, 26 | Abecassis Michael M | other | 0 |
| Mar 31, 26 | SCHECHTER JONATHAN | other | 0 |
| Mar 31, 26 | WEINSTEIN ROBERT | other | 0 |
| Mar 31, 26 | WEINSTEIN ROBERT | other | 119,170 |
| Mar 31, 26 | WALKER WAYNE REMELL | other | 119,170 |
| Mar 31, 26 | SCHECHTER JONATHAN | other | 119,170 |
| Mar 31, 26 | Abecassis Michael M | other | 119,170 |
| Jan 7, 26 | Silverman Joshua | buy | 40,000 |
| Jan 6, 26 | Silverman Joshua | buy | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PMCB coverage
Recent articles, reports, and earnings notes.
No research on PMCB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PMCB report →Nuvilex (NASDAQ:PMCB) Trading 5.3% Higher – Here’s Why
defenseworld.net · Apr 14
Comparing Nuvilex (NASDAQ:PMCB) & Avadel Pharmaceuticals (NASDAQ:AVDL)
defenseworld.net · Dec 5
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
businesswire.com · Nov 25
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
businesswire.com · Aug 20
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
businesswire.com · Aug 18
MyMD Pharmaceuticals Secures Strategic Investments
businesswire.com · May 21
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
businesswire.com · May 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.